Sélectionner la langue
Nectin-4
Nectin-4 Informations sur la molécule
| Nom anglais | Nectin-4 | Nombre de médicaments commercialisés | 1 |
| Nombre de médicaments cliniques | 29 | Alias de la cible | PRR4，LNIR，Nectin cell adhesion molecule 4，PVRL4，Ig superfamily receptor LNIR，Poliovirus receptor-related protein 4，NECTIN4，Poliovirus Receptor-Related 4，Nectin-4，Nectin 4，EDSS1 |
| Phase de R&D la plus avancée | Approved | ||
| Nom anglais | Nectin-4 |
| Alias de la cible | PRR4，LNIR，Nectin cell adhesion molecule 4，PVRL4，Ig superfamily receptor LNIR，Poliovirus receptor-related protein 4，NECTIN4，Poliovirus Receptor-Related 4，Nectin-4，Nectin 4，EDSS1 |
| Nombre de médicaments commercialisés | 1 |
| Nombre de médicaments cliniques | 29 |
| Phase de R&D la plus avancée | Approved |
Nectin-4 Liste de produits
- Attribut
Protein (23)Beads (1)Cell (1)Antibody (1)
- Bibliothèque de produits
En ligne (26)
- Espèces
Human (14)Mouse (6)Cynomolgus (4)Rat (2)
- Étiquette
His Tag (8)His Tag & Avi Tag (8)Fc Tag (4)- (3)Fc Tag & Avi Tag (3)
- Marqueur
Unconjugated (12)Biotin-labeled (10)FITC Labeled (1)- (2)PE Labeled (1)
Ajouter au panier
Quantité totale26
- 1
- 2
- 3
Nectin-4Contexte de la molécule
Nectin-4 (gene name PVRL4, poliovirus receptor-like 4) is a 66 kDa type I transmembrane glycoprotein belonging to the Nectin family of Ig superfamily proteins. Nectins are cell adhesion molecules that play a key role in various biological processes such as polarity, proliferation, differentiation and migration, for epithelial, endothelial, immune and neuronal cells, during development and adult life. Nectin-4 is a tumor-associated antigen in 50%, 49% and 86%o of breast, ovarian and lung carcinomas, respectively, mostly on tumors of bad prognosis. Its expression is not detected in the corresponding normal tissues.
Nectin-4Alias de la molécule
NECTIN4,LNIR, PRR4, PVRL4
Informations sur les médicaments cliniques
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Indication | Essai clinique |
|---|---|---|---|---|---|
| SYS-6002 | SYS-6002; SYS6002; CRB-701 | Phase 3 Clinical | CSPC Pharmaceutical Group Ltd, Jushi Biopharmaceutical Co Ltd | Carcinoma, Transitional Cell; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Uterine Cervical Neoplasms | Details |
| SHR-A2102 | SHR-A2102 | Phase 3 Clinical | Shanghai Hengrui Pharmaceutical Co Ltd | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Metastatic breast cancer; Neoplasms; Pancreatic Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms | Details |
| Bulumtatug fuvedotin | 9MW2821; 9MW-2821; 9-MW2821; 9-MW-2821 | Phase 3 Clinical | Mabwell (Shanghai) Bioscience Co Ltd | Carcinoma; Carcinoma, Transitional Cell; Genital Neoplasms, Female; Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Urologic Neoplasms; Uterine Cervical Neoplasms | Details |
| Zelenectide pevedotin | BT-8009 | Phase 3 Clinical | Bicycle Tx Ltd | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Ovarian Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms | Details |
| BT-7480 | BT-7480 | Phase 2 Clinical | Bicycle Therapeutics | Neoplasms; Solid tumours | Details |
| VBC-103 | AVZO-103; VAC-103; VBC-103; VBC103 | Phase 2 Clinical | VelaVigo Cayman Ltd | Carcinoma; Carcinoma, Transitional Cell; Solid tumours; Triple Negative Breast Neoplasms | Details |
| SC-101 | SC-101 | Phase 2 Clinical | Tianjin Conjustar Biotechnology Co Ltd | Breast Neoplasms; Solid tumours; Triple Negative Breast Neoplasms | Details |
| SKB-410 | SKB410; SKB-410; MK-3120 | Phase 2 Clinical | Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | Neoplasms; Solid tumours; Urinary Bladder Neoplasms | Details |
| PSMA/NKG2DL/FAP-targeted Hi-TCR-T cells | Phase 1 Clinical | Shenzhen Misheng Biotechnology Co Ltd | Prostatic Neoplasms; Solid tumours | Details | |
| BA-3361 | BA3361; BA-3361 | Phase 1 Clinical | Bioatla | Neoplasms | Details |
| ETx-22 | ETx-22; LY4101174 | Phase 1 Clinical | Emergence Therapeutics AG | Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Esophageal Neoplasms; Lung Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Pelvic Neoplasms; Prostatic Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms | Details |
| EB-DT-NK-UC101 | EB-DT-NK-UC101 | Phase 1 Clinical | Beijing Biotech | Carcinoma; Carcinoma, Transitional Cell; Urethral Neoplasms; Urinary Bladder Neoplasms | Details |
| 68Ga-Nectin-4 | Phase 1 Clinical | The First Affiliated Hospital Of Soochow University | Solid tumours | Details | |
| [64Cu]Cu-AKY-1189 | [64Cu]Cu-AKY-1189 | Phase 1 Clinical | Aktis Oncology Inc | Neoplasms | Details |
| AKY-1189 | AKY-1189; [225Ac]Ac-AKY-1189; 225Ac-AKY-1189 | Phase 1 Clinical | Aktis Oncology Inc | Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Colorectal Neoplasms; Head and Neck Neoplasms; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms | Details |
| AK-146-D-1 | AK146D1; AK-146-D1 | Phase 1 Clinical | Solid tumours | Details | |
| Nectin-4 targeting antibody drug conjugate 2 (Eli Lilly and Company) | Phase 1 Clinical | Eli Lilly And Company | Neoplasms | Details | |
| Nectin-4 targeting antibody drug conjugate 1 (Eli Lilly and Company) | Phase 1 Clinical | Eli Lilly And Company | Neoplasms | Details | |
| XKDCT-293 | XKDCT-293; XKDCT293 | Phase 1 Clinical | Shenzhen Celconta Life Science Co Ltd | Breast Neoplasms | Details |
| IPH-4502 | IPH4502; IPH-4502 | Phase 1 Clinical | Innate Pharma SA | Solid tumours | Details |
| LY-4052031 | LY-4052031 | Phase 1 Clinical | Eli Lilly & Company Lilly France | Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Esophageal Neoplasms; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Pelvic Neoplasms; Prostatic Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms | Details |
| RNDO-564 | RNDO-564 | Phase 1 Clinical | Rondo Therapeutics | Carcinoma; Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms | Details |
| ADRX-0706 | ADRX-0706 | Phase 1 Clinical | Adcentrx Therapeutics Inc | Carcinoma; Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms | Details |
| BAT-8007 | BAT-8007 | Phase 1 Clinical | Bio-Thera Solutions Ltd | Solid tumours | Details |
| Nectin-4 targeting radiopharmaceutical program (Aktis Oncology) | Clinical | Aktis Oncology Inc | Solid tumours | Details | |
| [68Ga]Ga-NOTA-RND20 | Clinical | Renji Hospital Affiliated To Shanghai Jiaotong University School Of Medicine | Digestive System Neoplasms | Details | |
| [18F]F-RESCA-RND20 | Clinical | Renji Hospital Affiliated To Shanghai Jiaotong University School Of Medicine | Digestive System Neoplasms | Details | |
| CT-341 | CT-341 | Clinical | Shenzhen Celconta Life Science Co Ltd | Breast Neoplasms | Details |
| 68Ga-N188 | 68Ga-N188; 68-Ga-N-188 | Clinical | Yunnan Baiyao Group Co Ltd | Carcinoma, Transitional Cell; Neoplasms | Details |
Informations sur les médicaments commercialisés
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Plus ancien nom de marque | Pays d'approbation le plus ancien | Indication la plus ancienne | Société d'approbation la plus ancienne | Date d'approbation la plus ancienne | Indication | Essai clinique |
|---|---|---|---|---|---|---|---|---|---|---|
| Enfortumab vedotin | AGS-22C3E; AGS-22C3; ASG-22CE; AGS-M6; ASG-22M6E; DLE8519RWM; ASG-22ME; AGS-22ME; AGS-22M6E | Approved | Agensys Inc, Seagen Inc | Padcev, 备思复 | United States | Carcinoma, Transitional Cell | Astellas Pharma Us Inc | 2019-12-18 | Carcinoma; Carcinoma in Situ; Carcinoma, Hepatocellular; Carcinoma, Pancreatic Ductal; Carcinoma, Transitional Cell; Colorectal Neoplasms; Endometrial Neoplasms; Intestinal Neoplasms; Kidney Neoplasms; Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Solid tumours; Ureteral Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Urologic Neoplasms | Details |
Avis sur les produits
O***s2022-07-30
0Mettre un likeWe used this for an important reagent in discovery campaigns. This was a great product! It came sooner than expected, which was awesome because we were able to easily make deadlines! It was also high quality. We didn't have any problems with it, so I am very happy with the quality of service and product. I will definitely buy again. Thank you very much.- 1***82019-10-11 8Mettre un likeI Purchased this antigen for monoclonal antibody generation and antibody screening. The purity has been test by SDS-PAGE. It has a single band and no heterologous protein. It was used for antibody screening, and the screened antibody has a good affinity with the antigen.
- Informations sur la molécule
- Liste de produits
- Informations sur les médicaments commercialisés
- Avis sur les produits
- Informations sur les médicaments cliniques
Partager vers :